Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations

Fig. 2

Development of active MTB in a patient treated with atezolizumab and cobimetinib for metastatic melanoma in the setting of a clinical trial. a Timeline of therapy and disease status for both melanoma and MTB. b Chest CT images of patient at the enrollment in the clinical trial (July 2018, left) and 4 months later (November 2018, right)

Back to article page